tiprankstipranks
Advertisement
Advertisement

SRPT Stock Latest News

Tractor Supply downgrade, Five Below upgraded: Wall Street’s top analyst calls
The FlyTractor Supply downgrade, Five Below upgraded: Wall Street’s top analyst calls
10d ago
AMT
CNK
Sarepta price target lowered to $20 from $23 at Piper Sandler
PremiumThe Fly
Sarepta price target lowered to $20 from $23 at Piper Sandler
10d ago
SRPT
Sarepta upgraded to Outperform from Peer Perform at Wolfe Research
PremiumThe Fly
Sarepta upgraded to Outperform from Peer Perform at Wolfe Research
10d ago
SRPT
H.C. Wainwright says Sarepta news does not signal full approvals
PremiumThe Fly
H.C. Wainwright says Sarepta news does not signal full approvals
18d ago
SRPT
Sarepta announces FDA acceptance of sNDAs for AMONDYS 45, VYONDYS 53
PremiumThe Fly
Sarepta announces FDA acceptance of sNDAs for AMONDYS 45, VYONDYS 53
19d ago
SRPT
Sarepta Shareholders Approve 2026 Equity and ESPP Plans
PremiumCompany AnnouncementsSarepta Shareholders Approve 2026 Equity and ESPP Plans
1M ago
8K
SRPT
Acting FDA head vows to block political interference, Endpoint News says
Premium
The Fly
Acting FDA head vows to block political interference, Endpoint News says
1M ago
AZN
BMY
SRPT Expands Into Huntington’s Disease With New First-in-Human Trial
Premium
Company Announcements
SRPT Expands Into Huntington’s Disease With New First-in-Human Trial
1M ago
SRPT
FDA issues draft guidance to help accelerated cell, gene therapies for patients
PremiumThe Fly
FDA issues draft guidance to help accelerated cell, gene therapies for patients
2M ago
AZN
BMY
Sarepta Therapeutics: Buy Rating Reiterated on Elevidys Uptake Outlook and Microdystrophin Validation; $35 Price Target Unchanged
PremiumRatings
Sarepta Therapeutics: Buy Rating Reiterated on Elevidys Uptake Outlook and Microdystrophin Validation; $35 Price Target Unchanged
2M ago
SRPT
Sarepta price target lowered to $19 from $20 at Evercore ISI
PremiumThe Fly
Sarepta price target lowered to $19 from $20 at Evercore ISI
2M ago
SRPT
FDA Commissioner Marty Makary resigns
PremiumThe Fly
FDA Commissioner Marty Makary resigns
2M ago
AZN
BMY
Trump Trade: Trump to suspend tariff-rate quotas on beef imports
PremiumThe FlyTrump Trade: Trump to suspend tariff-rate quotas on beef imports
2M ago
AZN
BMY
Trump Trade: U.S. plans AI security order without required model tests
Premium
The Fly
Trump Trade: U.S. plans AI security order without required model tests
2M ago
DYN
RNA
Trump approves plan to fire FDA head Marty Makary, CBS reports
Premium
The Fly
Trump approves plan to fire FDA head Marty Makary, CBS reports
2M ago
DYN
RNA
Sarepta Therapeutics: Pipeline Binary Risks and Elevidys Uptake Uncertainty Support Neutral Rating Through 2026
PremiumRatings
Sarepta Therapeutics: Pipeline Binary Risks and Elevidys Uptake Uncertainty Support Neutral Rating Through 2026
2M ago
SRPT
Sarepta Therapeutics: Hold Rating Reaffirmed as Strong Elevidys Sales Offset by Pipeline and Execution Uncertainties
PremiumRatings
Sarepta Therapeutics: Hold Rating Reaffirmed as Strong Elevidys Sales Offset by Pipeline and Execution Uncertainties
2M ago
SRPT
Gil Blum Reiterates Sell on Sarepta as Elevidys Momentum Slows and Regulatory Risks Mount
PremiumRatings
Gil Blum Reiterates Sell on Sarepta as Elevidys Momentum Slows and Regulatory Risks Mount
2M ago
SRPT
Sarepta Therapeutics: Safety Overhangs and Regulatory Uncertainty Reinforce Sell Rating and Unchanged $13 Price Target
PremiumRatings
Sarepta Therapeutics: Safety Overhangs and Regulatory Uncertainty Reinforce Sell Rating and Unchanged $13 Price Target
2M ago
SRPT
Ritu Baral Reiterates Hold on Sarepta, Maintains $17 Price Target Amid Mixed Operating Profile and Balanced Risk-Reward
PremiumRatingsRitu Baral Reiterates Hold on Sarepta, Maintains $17 Price Target Amid Mixed Operating Profile and Balanced Risk-Reward
2M ago
SRPT
Sarepta reports Q1 adjusted EPS $3.16 vs ($3.42) last year
Premium
The Fly
Sarepta reports Q1 adjusted EPS $3.16 vs ($3.42) last year
2M ago
SRPT
Sarepta Therapeutics Signals Profits Amid Alevitus Tests
Premium
Company Announcements
Sarepta Therapeutics Signals Profits Amid Alevitus Tests
2M ago
SRPT

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >